88,436 Shares in Vanda Pharmaceuticals Inc. (VNDA) Acquired by Ameriprise Financial Inc.

Ameriprise Financial Inc. acquired a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 88,436 shares of the biopharmaceutical company’s stock, valued at approximately $1,441,000. Ameriprise Financial Inc. owned about 0.20% of Vanda Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of VNDA. American International Group Inc. raised its position in Vanda Pharmaceuticals by 7.1% in the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock worth $316,000 after purchasing an additional 1,491 shares during the last quarter. FMR LLC raised its position in Vanda Pharmaceuticals by 60.7% in the 1st quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after purchasing an additional 604,900 shares during the last quarter. Teachers Advisors LLC raised its position in Vanda Pharmaceuticals by 1.0% in the 1st quarter. Teachers Advisors LLC now owns 535,861 shares of the biopharmaceutical company’s stock worth $7,502,000 after purchasing an additional 5,180 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in Vanda Pharmaceuticals by 5.1% in the 1st quarter. TIAA CREF Investment Management LLC now owns 408,952 shares of the biopharmaceutical company’s stock worth $5,725,000 after purchasing an additional 19,674 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Vanda Pharmaceuticals by 26.4% in the 1st quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after purchasing an additional 521,669 shares during the last quarter. Hedge funds and other institutional investors own 86.52% of the company’s stock.

VNDA has been the subject of several research analyst reports. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 26th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Piper Jaffray Companies set a $26.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 19th. Finally, ValuEngine lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Vanda Pharmaceuticals has an average rating of “Buy” and a consensus price target of $22.00.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/05/88436-shares-in-vanda-pharmaceuticals-inc-vnda-acquired-by-ameriprise-financial-inc.html.

Shares of Vanda Pharmaceuticals Inc. (NASDAQ VNDA) opened at $16.10 on Friday. Vanda Pharmaceuticals Inc. has a fifty-two week low of $12.70 and a fifty-two week high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm had revenue of $42.06 million during the quarter, compared to analyst estimates of $40.31 million. During the same quarter in the previous year, the business earned $0.01 EPS. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. analysts predict that Vanda Pharmaceuticals Inc. will post -0.42 earnings per share for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

What are top analysts saying about Vanda Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vanda Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit